Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association
Eugenia Gianos,P. Barton Duell,Peter P. Toth,Patrick M. Moriarty,Gilbert R. Thompson,Eliot A. Brinton,Lisa C. Hudgins,Mary Nametka,Kathleen H. Byrne,Geetha Raghuveer,Prashant Nedungadi,Laurence S. Sperling,on behalf of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; and Council on Peripheral Vascular Disease
DOI: https://doi.org/10.1161/atv.0000000000000177
2024-10-09
Arteriosclerosis Thrombosis and Vascular Biology
Abstract:Arteriosclerosis, Thrombosis, and Vascular Biology, Ahead of Print. Despite the availability of multiple classes of lipoprotein-lowering medications, some high-risk patients have persistent hypercholesterolemia and may require nonpharmacologic therapy. Lipoprotein apheresis (LA) is a valuable but underused adjunctive therapeutic option for low-density lipoprotein cholesterol and lipoprotein(a) lowering, particularly in children and adults with familial hypercholesterolemia. In addition to lipid lowering, LA reduces serum levels of proinflammatory and prothrombotic factors, reduces blood viscosity, increases microvascular myocardial perfusion, and may provide beneficial effects on endothelial function. Multiple observational studies demonstrate strong evidence for improved cardiovascular outcomes with LA; however, use in the United States is limited to a fraction of its Food and Drug Administration–approved indications. In addition, there are limited data regarding LA benefit for refractory focal segmental glomerulosclerosis. In this scientific statement, we review the history of LA, mechanisms of action, cardiovascular and renal outcomes data, indications, and options for treatment.
peripheral vascular disease,hematology